EPB0221	Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and body mass index: a subgroup analysis of the Phase 3b SOLAR study	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0222	A Bayesian update on discontinuation of cabotegravir and rilpivirine using cohort data	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0223	Real-world utilization and effectiveness of long-acting cabotegravir+rilpivirine in the United States: Trio Cohort study	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0224	Association of oral lead-in and persistence on cabotegravir and rilpivirine long-acting in ‘real-life’	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0225	A Site-driven CQI intervention improves advanced HIV disease screening coverage among newly diagnosed people living with HIV in Malawi	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0226	Changes in weight and body mass index associated with dolutegravir- and non-dolutegravir-based antiretroviral treatment regimens: a longitudinal analysis	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0227	Factors associated with viral rebound among PLHIV who achieved viral suppression in Eswatini: a retrospective cohort study	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0228	Towards colorimetric readout of a rapid enzymatic assay for measuring nucleotide analogs used in ART and PrEP	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0229	High treatment continuity established among people with HIV devolved to Community Pharmacy Antiretroviral Refill Program (CPARP) in Southern Nigeria	E-poster	Antiretroviral therapies and clinical issues in adults
EPB0230	Comparison of long-acting lenacapavir Phase 2/3 regimen vs simplified regimen using population-PK analysis and simulation	E-poster	Antiretroviral therapies and clinical issues in adults